Epidemiology of Bronchiectasis at a Single Center in Japan: a Retrospective Cohort Study

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2024 Oct 25

PMID 39448945

Authors

Kazuki Hashimoto

Yuko Abe

Kiyoharu Fukushima

Takayuki Niitsu

Sho Komukai

Satoshi Miyamoto

Takuro Nii

Takanori Matsuki

Noriyuki Takeuchi

Kozo Morimoto

Hiroshi Kida

Affiliations

Soon will be listed here.

Abstract

Background: The characteristics of bronchiectasis (BE) in Asia, including Japan, remain largely unknown. We aimed to provide insights into the clinical characteristics and treatment outcomes of BE, especially regarding nontuberculous mycobacteria (NTM) infection and its poorly understood impact on prognosis. We also aimed to clarify the effect of long-term macrolide antibiotic use in patients with BE, who had no history of exacerbations.

Methods: In this single-center, retrospective study, the medical records of patients who satisfied the BE criteria between January 1, 2012, and August 31, 2023, were reviewed. Severe exacerbations and mortality during the observation period were recorded. Baseline characteristics and overall survival of patients with and without NTM infection, and factors influencing the time to the first exacerbation and death were analyzed. Additionally, the effects of long-term macrolide antibiotic use in patients without a history of severe exacerbations were estimated.

Results: In a cohort of 1044 patients with BE, the rate of severe exacerbation was 22.3%, with mortality rates of 3.2% over 3 years. Notably, the high prevalence of NTM infection (n = 410, 39.3%) in this cohort was distinctive. NTM infection was not associated with either the time to first severe exacerbation (p = 0.5676, adjusted hazard ratio = 1.11) or mortality (p = 0.4139, adjusted hazard ratio = 0.78). Compared with the NTM group, the non-NTM group had a higher proportion of elevated inflammatory markers, with significant differences in C-reactive protein levels (p = 0.0301) and blood neutrophil counts (p = 0.0273). Pseudomonas aeruginosa colonization was more frequent in the non-NTM group (p = 0.0003). Among patients with non-NTM infection and without a history of exacerbation in the past 2 years, 38.2% received long-term macrolide antibiotics that did not invariably prolong the time to first severe exacerbation (p = 0.4517, IPW p = 0.3555).

Conclusions: This study highlights BE epidemiology in Japan, noting that the presence of NTM infection may not necessarily worsen the prognostic outcomes and advising caution in the casual use of macrolides for milder cases without a history of exacerbations.

Clinical Trial Registration: UMIN Clinical Trials Registry Number: UMIN000054726 (Registered on 21 June 2024).

References

Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K . A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc. 2013; 11(1):1-8. DOI: 10.1513/AnnalsATS.201303-067OC. View

Chalmers J, Polverino E, Crichton M, Ringshausen F, Soyza A, Vendrell M . Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir Med. 2023; 11(7):637-649. DOI: 10.1016/S2213-2600(23)00093-0. View

Choi H, Ryu S, Keir H, Giam Y, Dicker A, Perea L . Inflammatory Molecular Endotypes in Bronchiectasis: A European Multicenter Cohort Study. Am J Respir Crit Care Med. 2023; 208(11):1166-1176. DOI: 10.1164/rccm.202303-0499OC. View

Kitada S, Kobayashi K, Ichiyama S, Takakura S, Sakatani M, Suzuki K . Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med. 2007; 177(7):793-7. DOI: 10.1164/rccm.200705-771OC. View

Polverino E, Goeminne P, McDonnell M, Aliberti S, Marshall S, Loebinger M . European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017; 50(3). DOI: 10.1183/13993003.00629-2017. View

Daley C, Iaccarino J, Lange C, Cambau E, Wallace Jr R, Andrejak C . Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020; 56(1). PMC: 8375621. DOI: 10.1183/13993003.00535-2020. View

Kwok W, Man Ho J, Tam T, Ip M, Lam D . Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications. Respir Res. 2021; 22(1):132. PMC: 8080398. DOI: 10.1186/s12931-021-01729-5. View

KINNEY W . Bronchiectasis; a neglected disease. Dis Chest. 2010; 13(1):33-47. DOI: 10.1378/chest.13.1.33. View

Choate R, Aksamit T, Mannino D, Addrizzo-Harris D, Barker A, Basavaraj A . Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study. Respir Med. 2021; 177:106285. DOI: 10.1016/j.rmed.2020.106285. View

10.

Chalmers J, Boersma W, Lonergan M, Jayaram L, Crichton M, Karalus N . Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir Med. 2019; 7(10):845-854. DOI: 10.1016/S2213-2600(19)30191-2. View

11.

Kwok W, Teo K, Lau K, Ho J . High-sensitivity C-reactive protein level in stable-state bronchiectasis predicts exacerbation risk. BMC Pulm Med. 2024; 24(1):80. PMC: 10863114. DOI: 10.1186/s12890-024-02888-z. View

12.

ODonnell A . Bronchiectasis - A Clinical Review. N Engl J Med. 2022; 387(6):533-545. DOI: 10.1056/NEJMra2202819. View

13.

Shibata Y, Horita N, Yamamoto M, Tsukahara T, Nagakura H, Tashiro K . Diagnostic test accuracy of anti-glycopeptidolipid-core IgA antibodies for Mycobacterium avium complex pulmonary disease: systematic review and meta-analysis. Sci Rep. 2016; 6:29325. PMC: 4931691. DOI: 10.1038/srep29325. View

14.

Chalmers J, Moffitt K, Suarez-Cuartin G, Sibila O, Finch S, Furrie E . Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. Am J Respir Crit Care Med. 2016; 195(10):1384-1393. PMC: 5443898. DOI: 10.1164/rccm.201605-1027OC. View

15.

Aksamit T, ODonnell A, Barker A, Olivier K, Winthrop K, Daniels M . Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry. Chest. 2016; 151(5):982-992. PMC: 6026266. DOI: 10.1016/j.chest.2016.10.055. View

16.

Mahler D, Wells C . Evaluation of clinical methods for rating dyspnea. Chest. 1988; 93(3):580-6. DOI: 10.1378/chest.93.3.580. View

17.

Keir H, Shoemark A, Dicker A, Perea L, Pollock J, Giam Y . Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. Lancet Respir Med. 2021; 9(8):873-884. DOI: 10.1016/S2213-2600(20)30504-X. View

18.

Kelly M, Murphy S, Elborn J . Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med. 2004; 14(8):488-492. DOI: 10.1016/j.ejim.2003.10.002. View

19.

Hill A, Sullivan A, Chalmers J, Soyza A, Elborn S, Floto A . British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2018; 74(Suppl 1):1-69. DOI: 10.1136/thoraxjnl-2018-212463. View

20.

Kadowaki T, Yano S, Wakabayashi K, Kobayashi K, Ishikawa S, Kimura M . An analysis of etiology, causal pathogens, imaging patterns, and treatment of Japanese patients with bronchiectasis. Respir Investig. 2014; 53(1):37-44. DOI: 10.1016/j.resinv.2014.09.004. View